ACCP Clinical Reasoning Series in Pharmacotherapy, Home Study Edition Recorded Lecture, CE 2025 (Videos + Audios + Slides)

ACCP Clinical Reasoning Series in Pharmacotherapy, Home Study Edition Recorded Lecture, CE 2025

BCPS Pharmacotherapy • Clinical Reasoning • Oncology Pharmacotherapy • Immune Checkpoint Inhibitors • CAR-T / Immune Effector Cell Therapy • Asthma • COPD • Obstructive Sleep Apnea • Antithrombotic Therapy • ACS • Lipid Management • Cardiovascular Risk

The ACCP Clinical Reasoning Series in Pharmacotherapy, 2025 Home Study Edition is an advanced, application-based educational program designed for Board-Certified Pharmacotherapy Specialists (BCPS) and other clinical pharmacists seeking contemporary updates in complex pharmacotherapy and evidence-based clinical decision-making.

Approved by the Board of Pharmacy Specialties (BPS) as a component of ACCP’s professional development program for BCPS recertification, the 2025 series focuses on developing the pharmacist’s ability to critically evaluate scientific evidence, apply new therapeutic findings, individualize pharmacotherapy, and improve medication safety and clinical outcomes.

The program is organized into three major educational activities covering high-impact areas of contemporary practice:

1. Oncology Pharmacotherapy
2. Pulmonary Pharmacotherapy
3. Antithrombotic and Cardiovascular Risk Management

The 2025 curriculum addresses immune checkpoint inhibitors, immune effector cell therapies, CRS, ICANS, asthma, COPD, asthma-COPD overlap, biologic therapies, obstructive sleep apnea and obesity, vaccination, acute coronary syndrome, antiplatelet therapy, bleeding and ischemic risk, PREVENT cardiovascular risk assessment, coronary artery calcium, Lipoprotein(a), and emerging lipid-lowering therapies.

Course Details

• Course: Clinical Reasoning Series in Pharmacotherapy, 2025 Home Study Edition
• Provider: American College of Clinical Pharmacy (ACCP)
• Year: 2025
• Release Date: November 12, 2025
• Format: Recorded Lecture / Home Study
• Primary Focus: Advanced Pharmacotherapy and Clinical Reasoning
• Board Focus: Board-Certified Pharmacotherapy Specialist (BCPS) Recertification
• Official Educational Activities: 3
• Official Credit: Up to 6.0 Contact Hours
• Activity Type: Application-Based
• Language: English
• MedicalAmboss Package: Videos + Audios + Slides
• Official Media: Streaming Audio/Slide Presentations + MP3 + MP4 + Printable PDF Slides

The official ACCP version is available in formats that include CPE credit and, with the specialty recertification package, BCPS recertification credit.

Target Audience

The official target audience is:

• Board-Certified Pharmacotherapy Specialists (BCPS)
• Clinical pharmacists seeking BCPS recertification credit
• Pharmacists seeking advanced education in the covered therapeutic areas

The program is also highly relevant to:

• Clinical Pharmacists
• Hospital Pharmacists
• Ambulatory Care Pharmacists
• Oncology Pharmacists
• Cardiology Pharmacists
• Pulmonary Pharmacotherapy Specialists
• Internal Medicine Pharmacists
• Medication Safety Pharmacists
• Pharmacy Residents
• Pharmacy Fellows
• Pharmacists managing complex medication regimens
• Clinicians involved in evidence-based pharmacotherapy decisions

The series is particularly valuable for pharmacists who need to integrate rapidly changing therapeutic evidence into daily patient care.

Program Overview

The Clinical Reasoning Series in Pharmacotherapy 2025 is designed to strengthen clinical judgment rather than provide a simple disease-state review.

Each activity uses contemporary therapeutic issues to develop skills in:

• Critical appraisal of clinical evidence
• Patient-specific treatment selection
• Risk-benefit assessment
• Therapeutic monitoring
• Medication safety
• Recognition of adverse effects
• Application of updated guidelines
• Integration of novel therapies
• Case-based decision-making

The three activities span oncology, pulmonary medicine, and cardiovascular pharmacotherapy, providing a broad yet focused review of complex areas commonly encountered by pharmacotherapy specialists.

Official Educational Activities

Part 1 – Target on Oncology Pharmacotherapy

Updates, Safety, and Management of Immune Checkpoint Inhibitor and Immune Effector Cell Therapies

Faculty: Lauren Ice, Pharm.D., BCOP, BCPS

Pharmacy Supervisor, Cancer Health & Transplant
Corewell Health
Grand Rapids, Michigan

This activity focuses on the rapidly expanding use of immunotherapy in cancer treatment and the pharmacist’s role in recognizing, monitoring, and managing treatment-related complications.

The session reviews both immune checkpoint inhibitor therapy and immune effector cell therapy, emphasizing therapeutic monitoring, adverse event recognition, toxicity differentiation, and clinical management.

Learning Objectives

Participants should be able to:

• Compare mechanisms and indications of immune checkpoint inhibitor and immune effector cell therapies.
• Recognize the clinical presentation of immune checkpoint inhibitor-related toxicities.
• Design therapeutic monitoring plans for immune checkpoint inhibitor therapy.
• Differentiate cytokine release syndrome (CRS) from immune effector cell-associated neurotoxicity syndrome (ICANS).
• Develop management strategies for toxicities associated with immune effector cell therapy.

Major Oncology Topics

• Immune Checkpoint Inhibitors
• Immune Effector Cell Therapy
• Cancer Immunotherapy
• Therapeutic Monitoring
• Immune-Related Adverse Events
• Cytokine Release Syndrome
• CRS
• ICANS
• Immune-Mediated Toxicity
• Oncology Medication Safety
• Pharmacotherapy Monitoring
• Management of Immunotherapy Toxicities

Official Credit: 1.50 contact hours

Part 2 – Revolutionizing Pulmonary Care

Integrating Medication Management into Practice

Faculty: Jessica L. Wallace, Pharm.D., BCPS

Associate Professor
Department of Pharmacy and Pharmaceutical Sciences
Lipscomb University College of Pharmacy

Clinical Pharmacy Specialist
Veterans Affairs Tennessee Valley Healthcare System / Vanderbilt University Medical Center
Nashville, Tennessee

This activity reviews contemporary pulmonary pharmacotherapy with emphasis on new and emerging medications for asthma, chronic obstructive pulmonary disease (COPD), and obstructive sleep apnea with comorbid obesity.

It also addresses the clinical challenge of asthma-COPD overlap, severe pulmonary disease, biologic therapies, immunization strategies, and individualized medication monitoring.

The session highlights the pharmacist’s role in patient education, vaccination, disease-specific treatment selection, and optimization of therapy.

Learning Objectives

Participants should be able to:

• Differentiate the clinical features and management approaches of asthma, COPD, and asthma-COPD overlap.
• Review newly approved and emerging therapies for asthma and COPD.
• Incorporate current guideline-recommended immunizations into comprehensive pulmonary care.
• Evaluate the potential benefits of weight-loss treatment in patients with obesity and obstructive sleep apnea.
• Design individualized treatment plans for patients with overlapping pulmonary conditions.

Major Pulmonary Topics

• Asthma
• COPD
• Asthma-COPD Overlap
• Severe Asthma
• Severe COPD
• Biologic Therapies
• Emerging Pulmonary Medications
• Pulmonary Medication Monitoring
• Immunization in Pulmonary Disease
• Obstructive Sleep Apnea
• Obesity and Sleep-Related Breathing Disorders
• Weight-Loss Therapy
• Patient Education
• Personalized Pulmonary Pharmacotherapy

Official Credit: 1.50 contact hours

Part 3 – Managing Risk

Transitions in Antithrombotic Therapy and Lipid Medication Management

Faculty:

Amanda G. Sowder, Pharm.D., BCCP

Interventional Cardiology & Electrophysiology Laboratory Pharmacist
AdventHealth Orlando

Maria C. Coyle, Pharm.D., B.S.Pharm, FCCP, BCACP, BCPS, CLS

Professor – Clinical
The Ohio State University College of Pharmacy

Specialty Pharmacist – Ambulatory
The Ohio State University Wexner Medical Center
Columbus, Ohio

This activity addresses two major areas of cardiovascular pharmacotherapy:

• Peri-ACS and antithrombotic medication management
• Cardiovascular risk prediction and lipid-lowering therapy

It provides practical guidance on antiplatelet medication selection, timing of therapy, ischemic and bleeding risk assessment, therapeutic monitoring, and medication transitions during different stages of cardiovascular care.

The lipid-management component examines modern cardiovascular risk assessment, compares traditional pooled cohort equations with the PREVENT model, reviews coronary artery calcium guidance, and explores emerging therapies targeting Lipoprotein(a) and other residual cardiovascular risk factors.

What A Thrill! Launching Into Peri-ACS Antithrombotic Therapies

This component focuses on antiplatelet management in acute coronary syndromes.

Topics include:

• Acute Coronary Syndrome
• Antiplatelet Therapy
• NSTE-ACS
• Upstream Antiplatelet Therapy
• Dosing Strategies
• Ischemic Risk
• Bleeding Risk
• Risk Scoring
• Patient-Specific Medication Selection
• Peri-Procedural Antithrombotic Therapy
• Therapeutic Monitoring

Learning Objectives

Participants should be able to:

• Distinguish among available antiplatelet options for acute coronary syndromes.
• Evaluate upstream antiplatelet administration timing in NSTE-ACS.
• Apply ischemic and bleeding risk scoring tools.
• Choose individualized dosing strategies for specific patient scenarios.

Catching the Wave of Integrated Care: Predictive Models and Emerging Therapies in Cardiovascular Risk Management

This component focuses on contemporary cardiovascular prevention and lipid pharmacotherapy.

Topics include:

• Cardiovascular Risk Assessment
• Cardiometabolic Risk
• Chronic Kidney Disease Risk
• Pooled Cohort Equations
• PREVENT Risk Model
• Coronary Artery Calcium
• Statin Therapy
• Lipid-Lowering Therapy
• Emerging Lipid Therapies
• Lipoprotein(a)
• Residual Cardiovascular Risk
• Integrated Cardiovascular-Kidney-Metabolic Care

Learning Objectives

Participants should be able to:

• Develop comprehensive care plans integrating cardiovascular, kidney, and metabolic treatment targets.
• Compare factors influencing cardiovascular risk estimation using pooled cohort equations and PREVENT.
• Apply coronary artery calcium recommendations to clinical decision-making.
• Evaluate emerging treatments targeting Lipoprotein(a) in high-risk patients.

Official Credit: 3.00 contact hours

Major Topics Covered

• Clinical Pharmacotherapy
• BCPS Recertification
• Clinical Reasoning
• Evidence-Based Medicine
• Medication Safety
• Patient-Specific Pharmacotherapy
• Oncology Pharmacotherapy
• Cancer Immunotherapy
• Immune Checkpoint Inhibitors
• Immune Effector Cell Therapy
• CAR-T Related Toxicity
• Immune-Related Adverse Events
• Cytokine Release Syndrome
• CRS
• ICANS
• Therapeutic Monitoring
• Asthma
• COPD
• Asthma-COPD Overlap
• Severe Pulmonary Disease
• Biologic Therapy
• Emerging Pulmonary Medications
• Immunization
• Obstructive Sleep Apnea
• Obesity
• Weight-Loss Therapy
• Cardiovascular Pharmacotherapy
• Acute Coronary Syndrome
• ACS
• NSTE-ACS
• Antiplatelet Therapy
• Antithrombotic Therapy
• Bleeding Risk
• Ischemic Risk
• Cardiovascular Risk Assessment
• PREVENT Risk Model
• Pooled Cohort Equations
• Coronary Artery Calcium
• Dyslipidemia
• Statin Therapy
• Emerging Lipid-Lowering Agents
• Lipoprotein(a)
• Cardiometabolic Risk
• Cardiovascular-Kidney-Metabolic Care
• Case-Based Pharmacotherapy
• Therapeutic Decision-Making
• Clinical Evidence Evaluation

Program Chair

Alyssa Robertson, Pharm.D., BCCCP, BCEMP, BCPS

Clinical Pharmacist Specialist – Emergency Medicine
WellSpan York Hospital
York, Pennsylvania

Faculty

Lauren Ice, Pharm.D., BCOP, BCPS

Pharmacy Supervisor, Cancer Health & Transplant
Corewell Health
Grand Rapids, Michigan

Jessica L. Wallace, Pharm.D., BCPS

Associate Professor
Lipscomb University College of Pharmacy

Clinical Pharmacy Specialist
Veterans Affairs Tennessee Valley Healthcare System / Vanderbilt University Medical Center
Nashville, Tennessee

Amanda G. Sowder, Pharm.D., BCCP

Interventional Cardiology & Electrophysiology Laboratory Pharmacist
AdventHealth Orlando

Maria C. Coyle, Pharm.D., B.S.Pharm, FCCP, BCACP, BCPS, CLS

Professor – Clinical
The Ohio State University College of Pharmacy

Specialty Pharmacist – Ambulatory
The Ohio State University Wexner Medical Center
Columbus, Ohio

Official Continuing Education and BCPS Recertification

The official 2025 Home Study Edition includes:

• 3 application-based activities
• Up to 6.0 hours of CPE
• Up to 6.0 hours of BCPS recertification credit

The individual activities provide:

• Oncology Pharmacotherapy – 1.50 hours
• Pulmonary Care – 1.50 hours
• Antithrombotic & Lipid Management – 3.00 hours

The official dates are:

• Release Date: November 12, 2025
• BCPS Recertification Deadline: November 12, 2026
• ACPE Deadline: October 20, 2028

ACCP is accredited by the Accreditation Council for Pharmacy Education (ACPE) and is approved by BPS as a provider for BCPS recertification.

Important: Official CPE and BCPS recertification credit require eligible participation through ACCP and successful completion of the required posttests. Access to educational video, audio, or slide files alone does not independently provide official CPE or recertification credit.

Course Media

The official ACCP Home Study Edition provides:

• Streaming audio/slide-synchronized presentations
• Downloadable MP3 audio files
• Downloadable MP4 video files
• Downloadable and printable PDF presentation slides

The MedicalAmboss package includes Videos + Audios + Slides, allowing learners to:

• Watch the recorded lectures
• Listen to lectures separately
• Review slides independently
• Repeat complex clinical sections
• Combine audiovisual and slide-based study
• Study at their own pace

The ACCP product page confirms these official media formats.

Why This Course Is Relevant

The ACCP Clinical Reasoning Series in Pharmacotherapy 2025 is especially relevant for experienced clinical pharmacists because it focuses on therapeutic areas where evidence and practice are evolving rapidly.

The program is valuable for pharmacists seeking current education in:

• Cancer immunotherapy
• Immune checkpoint inhibitor toxicity
• Immune effector cell therapy
• CRS and ICANS
• Pulmonary pharmacotherapy
• Asthma and COPD differentiation
• Biologic therapy
• Asthma-COPD overlap
• Obesity-related obstructive sleep apnea
• Immunization recommendations
• Acute coronary syndrome
• Antiplatelet therapy
• Ischemic versus bleeding risk
• Cardiovascular risk prediction
• PREVENT risk assessment
• Coronary artery calcium
• Lipid management
• Lipoprotein(a)
• Emerging cardiovascular therapies
• Evidence-based clinical reasoning

Rather than offering a broad survey of pharmacotherapy, this series focuses on high-value contemporary therapeutic problems and challenges learners to translate emerging evidence into safe, individualized patient-care decisions.

Short Description

ACCP Clinical Reasoning Series in Pharmacotherapy, 2025 Home Study Edition provides advanced BCPS-focused education in oncology immunotherapy, pulmonary pharmacotherapy, antithrombotic therapy, and cardiovascular risk management. Topics include immune checkpoint inhibitors, immune effector cell therapy, CRS, ICANS, asthma, COPD, biologics, obstructive sleep apnea, acute coronary syndromes, antiplatelet therapy, PREVENT risk assessment, coronary artery calcium, Lipoprotein(a), and emerging lipid therapies.

The MedicalAmboss package includes Videos + Audios + Slides for flexible self-paced review.

+ Topics:

• 01 Oncology Pharmacotherapy – Contemporary Clinical Reasoning for Cancer Medication Therapy, Monitoring, Safety, and Patient-Specific Treatment
• 02 Immune Checkpoint Inhibitors – Mechanisms, Indications, Monitoring, and Recognition of Immune-Related Adverse Events
• 03 Immune Effector Cell Therapy – Clinical Use, Therapeutic Monitoring, and Management of Treatment-Related Complications
• 04 Cytokine Release Syndrome – Recognition, Differentiation, Severity Assessment, and Management of CRS After Immune Effector Cell Therapy
• 05 ICANS Neurotoxicity – Identifying and Managing Immune Effector Cell-Associated Neurotoxicity Syndrome
• 06 Immunotherapy Medication Safety – Monitoring Organ Toxicity, Adverse Events, and Treatment-Related Complications in Oncology Patients
• 07 Asthma Pharmacotherapy – Clinical Differentiation, Updated Treatment Options, Biologic Therapy, and Individualized Medication Management
• 08 COPD Pharmacotherapy – Contemporary Medication Selection, Emerging Therapies, Monitoring, and Patient-Centered Treatment
• 09 Asthma-COPD Overlap – Identifying Overlapping Clinical Features and Developing Individualized Pharmacotherapy Strategies
• 10 Severe Pulmonary Disease – Integrating Biologic Agents and Emerging Therapies Into Asthma and COPD Management
• 11 Pulmonary Immunization Strategies – Incorporating Current Vaccination Recommendations Into Comprehensive Respiratory Care
• 12 Obesity and Obstructive Sleep Apnea – Evaluating Weight-Loss Treatment as Part of Integrated Sleep-Related Pulmonary Care
• 13 Acute Coronary Syndrome Pharmacotherapy – Evidence-Based Antiplatelet Selection and Medication Management in ACS
• 14 NSTE-ACS Antiplatelet Strategies – Timing, Dosing, Upstream Therapy, and Patient-Specific Treatment Decisions
• 15 Ischemic and Bleeding Risk – Applying Clinical Risk Scores to Balance Cardiovascular Protection and Medication Safety
• 16 Peri-Procedural Antithrombotic Therapy – Medication Transitions, Therapeutic Monitoring, and Individualized Management Around Procedures
• 17 Cardiovascular Risk Assessment – Comparing Pooled Cohort Equations With the PREVENT Cardiovascular Risk Model
• 18 Coronary Artery Calcium – Applying CAC Guidance to Refine Cardiovascular Risk and Lipid-Treatment Decisions
• 19 Statin Therapy and Lipid Management – Patient Selection, Risk-Based Treatment Decisions, and Contemporary Dyslipidemia Pharmacotherapy
• 20 Lipoprotein(a) – Emerging Therapeutic Strategies for Residual Cardiovascular Risk Reduction in High-Risk Patients
• 21 Cardiovascular-Kidney-Metabolic Care – Integrating Cardiovascular, Renal, and Metabolic Treatment Targets in Complex Patients
• 22 Emerging Lipid-Lowering Therapies – Novel Pharmacologic Approaches and Their Potential Role in Cardiovascular Event Prevention
• 23 Clinical Evidence Evaluation – Critically Appraising Contemporary Therapeutic Literature and Applying Findings to Practice
• 24 Medication Monitoring and Safety – Designing Patient-Specific Monitoring Plans Across Oncology, Pulmonary, and Cardiovascular Therapy
• 25 BCPS Clinical Reasoning – Translating Scientific Evidence Into Safe, Effective, Individualized Pharmacotherapy Decisions